SCOTUS verdict shines on Caraco in generic 'Orange Book' battle
This article was originally published in Scrip
Sun Pharmaceutical US unit Caraco Pharmaceutical won a major victory for all generic drug makers on 17 April when the US Supreme Court ruled in a unanimous decision that those firms may employ the so-called counterclaim provision of the Hatch-Waxman Act to force brand-name drug manufacturers to correct inaccurate descriptions of their medication's patent as covering a particular method of using the product.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.